Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omarigliptin vs Glimepiride in T2DM on Metformin
NCT01682759Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of omarigliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Sep 2012; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01682759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682759.